Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 1
2015 2
2016 2
2017 1
2018 1
2020 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.
Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D. Pardi N, et al. Among authors: naradikian ms. J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8. J Exp Med. 2018. PMID: 29739835 Free PMC article.
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors.
Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, Ramamoorthy Premlal AL, Griswold RQ, Dolina JS, Cohen EEW, Miller AM, Peters B, Schoenberger SP. Brightman SE, et al. Among authors: naradikian ms. Nat Immunol. 2023 Aug;24(8):1345-1357. doi: 10.1038/s41590-023-01543-9. Epub 2023 Jul 3. Nat Immunol. 2023. PMID: 37400675 Free PMC article.
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Brightman SE, Naradikian MS, Miller AM, Schoenberger SP. Brightman SE, et al. Among authors: naradikian ms. J Leukoc Biol. 2020 Apr;107(4):625-633. doi: 10.1002/JLB.5RI0220-603RR. Epub 2020 Mar 14. J Leukoc Biol. 2020. PMID: 32170883 Free PMC article. Review.
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer.
Miller AM, Koşaloğlu-Yalçın Z, Westernberg L, Montero L, Bahmanof M, Frentzen A, Lanka M, Logandha Ramamoorthy Premlal A, Seumois G, Greenbaum J, Brightman SE, Soria Zavala K, Thota RR, Naradikian MS, Makani SS, Lippman SM, Sette A, Cohen EEW, Peters B, Schoenberger SP. Miller AM, et al. Among authors: naradikian ms. Sci Transl Med. 2024 Feb 28;16(736):eabj9905. doi: 10.1126/scitranslmed.abj9905. Epub 2024 Feb 28. Sci Transl Med. 2024. PMID: 38416845
Author Correction: Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors.
Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, Ramamoorthy Premlal AL, Griswold RQ, Dolina JS, Cohen EEW, Miller AM, Peters B, Schoenberger SP. Brightman SE, et al. Among authors: naradikian ms. Nat Immunol. 2023 Aug;24(8):1391. doi: 10.1038/s41590-023-01591-1. Nat Immunol. 2023. PMID: 37464051 Free PMC article. No abstract available.
HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen.
Mock JY, Winters A, Riley TP, Bruno R, Naradikian MS, Sharma S, Jette CA, Elshimali R, Gahrs C, Toledo-Warshaviak D, West AP Jr, Kamb A, Hamburger AE. Mock JY, et al. Among authors: naradikian ms. Mol Ther Oncolytics. 2022 Oct 4;27:157-166. doi: 10.1016/j.omto.2022.09.010. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36381658 Free PMC article.
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
Tokatlian T, Asuelime GE, Mock JY, DiAndreth B, Sharma S, Toledo Warshaviak D, Daris ME, Bolanos K, Luna BL, Naradikian MS, Deshmukh K, Hamburger AE, Kamb A. Tokatlian T, et al. Among authors: naradikian ms. J Immunother Cancer. 2022 Jan;10(1):e003826. doi: 10.1136/jitc-2021-003826. J Immunother Cancer. 2022. PMID: 35091455 Free PMC article.
17 results